{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:44:14Z","timestamp":1776689054943,"version":"3.51.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of neoadjuvant hormonal therapy (NHT) on perioperative and oncological outcomes in patients with oligometastatic prostate cancer (OmPCa) treated with robot-assisted radical prostatectomy (RARP) and adjuvant androgen-deprivation therapy (ADT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter retrospective study, 160 OmPCa patients treated from five Chinese medical centers between May 2010 and May 2023 were included: 80 received NHT followed by RARP+ADT, and 80 underwent RARP+ADT alone. We evaluated surgical information, pathological findings, biochemical progression-free survival (bPFS), radiological progression-free survival (rPFS), overall survival (OS), subsequent treatments, and ADT-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to the standard therapy (ST) group, the NHT group exhibited shorter operative time (170 vs. 200min; P\u00a0=\u00a00.030), less blood loss (100 vs. 200 mL; P\u00a0=\u00a00.022), lower positive surgical margin rate (17.50% vs. 37.50%; P\u00a0=\u00a00.005), and higher rates of pathological downstaging in T-stage (48.8% vs. 6.3%; P&amp;lt;0.001). More NHT patients achieved undetectable PSA (83.8% vs. 65.0%; P\u00a0=\u00a00.007) with a shorter time to PSA nadir (2 vs. 3 months; P\u00a0=\u00a00.002). After a median postoperative follow-up of 52 months, no significant differences were observed in bPFS, rPFS or OS between groups. However, subgroup analysis revealed significant interaction effects between NHT and biopsy Gleason score \u22658, seminal vesicle invasion, and clinical T stage \u2265 T3 (all P-interaction&amp;lt;0.05), with these subgroups showing significantly improved bPFS, rPFS and OS. Furthermore, patients in the NHT group received fewer subsequent treatments (32.5% vs. 47.5%, P\u00a0=\u00a00.031), and the incidence of ADT-related adverse events was comparable between the two groups (all P &amp;gt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NHT improves perioperative outcomes and reduces the need for subsequent salvage therapies in OmPCa patients undergoing RARP. It may offer oncological benefits, particularly those with a biopsy Gleason score \u22658 or clinical T-stage\u2265T3. It represents a safe and feasible neoadjuvant approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1765517","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:30Z","timestamp":1774506810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of neoadjuvant hormonal therapy combined with robot-assisted radical prostatectomy for oligometastatic prostate cancer: a multicenter retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yujie","family":"Dong","sequence":"first","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital, Soochow Medical College, Soochow University","place":["Soochow, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieping","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Jia","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanxin","family":"Zou","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinqiao","family":"Li","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiming","family":"Yang","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital, Soochow Medical College, Soochow University","place":["Soochow, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[{"name":"Senior Department of Urology, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-z","article-title":"The multistep nature of cancer","volume":"9","author":"Vogelstein","year":"1993","journal-title":"Trends Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1200\/JCO.2005.04.2226","article-title":"Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis","volume":"24","author":"Rapiti","year":"2006","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.ejso.2008.01.022","article-title":"Liver resection for metastatic gastric cancer","volume":"34","author":"Thelen","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02715-x","article-title":"Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis","volume":"20","author":"Mao","year":"2022","journal-title":"World J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4111\/icu.20230058","article-title":"Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: an updated systematic review and meta-analysis","volume":"64","author":"Chung","year":"2023","journal-title":"Investig Clin Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/iju.15540","article-title":"Local treatment benefits patients with oligometastatic prostate cancer: a systematic review and meta\u2010analysis","volume":"31","author":"Sun","year":"2024","journal-title":"Int J Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/JS9.0000000000001968","article-title":"Evaluating the effectiveness of cytoreductive surgery in oligometastatic prostate cancer: insights from quantitative analysis and retrospective cohort studies","volume":"111","author":"Cheng","year":"2025","journal-title":"Int J Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.clgc.2021.02.004","article-title":"Efficacy of neoadjuvant chemohormonal therapy in oligometastatic hormone-sensitive prostate cancer: a prospective, three-arm, comparative propensity score match analysis","volume":"19","author":"Chi","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1480861","article-title":"A retrospective study of neoadjuvant novel hormonal therapy prior to radical prostatectomy for high-risk prostate cancer","volume":"15","author":"Shuai","year":"2025","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/pcan.2017.29","article-title":"The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer","volume":"20","author":"Tosco","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/JU.0000000000002803","article-title":"Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis","volume":"208","author":"Ravi","year":"2022","journal-title":"J Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/aja.aja_88_20","article-title":"Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2021","journal-title":"Asian J Androl"},{"key":"B16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-20-3337","article-title":"(Oligo)metastasis as a spectrum of disease","volume":"81","author":"Gutiontov","year":"2021","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","article-title":"Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial","volume":"88","author":"Sherry","year":"2025","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1126\/science.156.3778.1050","article-title":"Endocrine-induced regression of cancers","volume":"136","author":"Huggins","year":"1978","journal-title":"Am J Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.23736\/S2724-6051.24.05630-1","article-title":"The role of androgen deprivation therapy prior to radical prostatectomy in high-risk prostate cancer: a systematic review","volume":"76","author":"Arroyo-Rojas","year":"2024","journal-title":"Minerva Urol Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ijrobp.2016.08.043","article-title":"Salvage radiation therapy dose response for biochemical failure of prostate cancer after prostatectomy: a multi-institutional observational study","volume":"96","author":"Pisansky","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41379-020-0625-x","article-title":"Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients","volume":"34","author":"Hollemans","year":"2021","journal-title":"Mod Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/PAP.0000000000000347","article-title":"Neoadjuvant hormonal therapy for prostate cancer: morphologic features and predictive parameters of therapy response","volume":"29","author":"Wang","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1078-0432.CCR-22-1768","article-title":"Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit","volume":"29","author":"Mascarella","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/pros.24754","article-title":"Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients","volume":"84","author":"Wenzel","year":"2024","journal-title":"Prostate"},{"key":"B29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/JU.0000000000004089","article-title":"Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer: an exploratory analysis of the TITAN trial","volume":"212","author":"Roy","year":"2024","journal-title":"J Urol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/pros.24880","article-title":"Rapid and deep prostate-specific antigen decline is a prognostic marker in metastatic hormone-sensitive prostate cancer: a real-world multi-institutional analysis","volume":"85","author":"Suzuki","year":"2025","journal-title":"Prostate"},{"key":"B31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/00005392-199508000-00026","article-title":"Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group","volume":"154","author":"Soloway","year":"1995","journal-title":"J Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000474242","article-title":"Effects of neoadjuvant androgen deprivation therapy on prostatic cancer","volume":"30","author":"Polito","year":"1996","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/0960-0760(90)90448-t","article-title":"Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience","volume":"37","author":"Labrie","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00432-007-0204-2","article-title":"Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy","volume":"133","author":"Pu","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/j.ijrobp.2023.06.1559","article-title":"Effect of adjuvant chemotherapy in highly malignant non-metastatic prostate cancer: an interim analysis of non-randomized comparative trials","volume":"117","author":"Li","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2018.12.003","article-title":"Pelvic complications after prostate cancer radiation therapy and their management: an international collaborative narrative review","volume":"75","author":"Matta","year":"2019","journal-title":"Eur Urol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/PROM.S52788","article-title":"Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes","volume":"5","author":"Ahmadi","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"B38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clgc.2022.10.009","article-title":"Perioperative morbidity of radical prostatectomy after intensive neoadjuvant androgen blockade in men with high-risk prostate cancer: results of phase II trial compared to a control group","volume":"21","author":"Ilario","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1097\/JU.0000000000001646","article-title":"The clinical significance of bone mineral density changes following long-term androgen deprivation therapy in localized prostate cancer patients","volume":"205","author":"Khriguian","year":"2021","journal-title":"J Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:35Z","timestamp":1774506815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1765517"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1765517","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1765517"}}